In VivoAs the recently appointed head of global commercial market strategy and insights at Bristol Myers Squibb (BMS), Doxie Jordan represents the integration of strategic commercial expertise with purpose-d
ScripWelsh biotech Draig Therapeutics has come out of stealth backed by an impressive line-up of healthcare investors and led by a highly experienced leadership team as it bids to become a major player in
ScripBristol Myers Squibb’s CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) may see an expansion in its addressable population with positive Phase II data in marginal zone lymphoma (MZL). The drugma
ScripNuvation is transitioning into a commercial-stage biopharma with the launch of Ibtrozi (taletrectinib) for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), where it will compete agai